This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Mixed picture: 2 strengths against 2 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
In plain words
Stock 6931 shows high profitability with a return on equity of 18.6% and a net margin of 19.4%, while its P/E ratio of 9.58 is lower than the Biotechnology and medical median of 15.31. However, it presents a mixed picture as liabilities reached 56.1% of total assets in Q3 2026 and free cash flow was negative at -152 NT$ million in 2025. Additionally, there is one verified alert from 2026-11-11 and two filings are currently held or rejected awaiting human review. Ultimately, final investment decisions rest entirely with the investor.
Written by gemini-3.6-flash from the facts above; every number was checked against them.
Strengths
+P/E 9.58 is well below the Biotechnology and medical median of 15.31 (38 listed peers): priced cheaper than peers. source (Key Stats) →
+Return on equity 18.6% with a 19.4% net margin: highly profitable. source (Key Stats) →
Watch-outs
!Liabilities are 56.1% of total assets (Q3 2026): a heavy debt load. source (Financials) →
!Free cash flow was negative in 2025: -152 NT$ million, so spending exceeded operating cash. source (Financials) →
What to check before deciding
?Can operating cash cover the debt if conditions tighten?
?What is the spending for, and when does it start paying back?
What the analysis found
+Valuation vs peersP/E 9.58 is well below the Biotechnology and medical median of 15.31 (38 listed peers): priced cheaper than peers. source →
+ProfitabilityReturn on equity 18.6% with a 19.4% net margin: highly profitable. source →
!DebtLiabilities are 56.1% of total assets (Q3 2026): a heavy debt load. source →
!Cash flowFree cash flow was negative in 2025: -152 NT$ million, so spending exceeded operating cash. source →
·Filings1 verified alert(s); latest on 2026-11-11: 公告本公司董事會通過115年第三季合併財務報告 source →
·Filings2 filing(s) are held or rejected and wait for human review. source →